To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).
New York, New York 10032, United States
Women or men age >18 years
Diagnosed with stage I-III breast cancer prescribed endocrine therapy
Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation)
Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention
Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire
Evidence of breast cancer recurrence
Non-English or Non-Spanish speaking
Not cognitively able to complete study requirements
Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR
Inability to provide informed consent
Study Contact Info
Contact Listings Owner Form
IMPACT Trial: Intervention to iMProve AdherenCe Equitably 0 reviewsWrite Your Review
There are no reviews yet.